Current Support
Jubilant Draximage & Public Health Institute (ANBL1531), “A phase III study of 1311 Metaiodobenzylguanidine (131I-MIBG) or Crizotinib added to intensive therapy for children with newly diagnosed high-risk neuroblastoma” (2022-xxxx). DeSantes, site PI
LLS Pedal Initiative, LLC & Public Health Institute (APAL2020SC), “Pediatric acute leukemia (PedAL) screening trial developing new therapies for relapsed leukemias” (2022-xxxx). DeSantes, site PI
AstraZeneca & Public Health Institute (ACNS1831), “A phase 3 randomized study of selumetinib versus carboplatin/vincristine in children with newly diagnosed or previously untreated neurofibromatosis type 1 (NF1) associated low-grade glioma (LGG) (CRADA 02172)” (2022-xxxx). DeSantes, site PI
Public Health Institute (ACNS1833), “Comparing functional and quality of life outcomes after selumetinib vs. carboplatin/vincristine in children with newly diagnosed low-grade glioma” (2022-xxxx). DeSantes, site PI
Springworks Therapeutics & Public Health Institute (ARST1921), “A safety, pharmacokinetic and efficacy study of a gamma-secretase inhibitor, nirogacestat (PF 03084014; IND# 146375), in children and adolescents with progressive, surgically unresectable desmoid tumors” (2021-xxxx). DeSantes, site PI
NIH & Children’s Hospital of Philadelphia (ACCL1633), “The effectiveness of lactobacillus plantarum (LBP, IND# 17339) in preventing acute graft-versus-host disease (GvHD) in children undergoing alternative hematopoietic progenitor cell transplantation (HCT)” (2021-xxxx). DeSantes, site PI
Clarity Pharmaceuticals, “Cu-sartate peptide receptor radionuclide therapy administered to pediatric patients with high-risk neuroblastoma: A multi-center, dose-escalation, open label, non-randomized, phase 1/2a theranostic clinical trial” (2021-xxxx). DeSantes, PI
NIH/NCI & Public Health Institute (U10 CA180886), “COG national clinical trials network workload intensity” (2021-2025). DeSantes, site PI
NIH/NIAID & Children’s Hospital of Los Angeles (U01 AI126612), “A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCRaB+/CD19+ depleted transplantation” (2019-xxxx). DeSantes, site PI
Novartis & Children’s Hospital of Philadelphia (AALL1721), “A single arm phase II trial to assess the efficacy & safety of CTL019 in first line high-risk pediatric & young adult patients with B-cell acute lymphoblastic leukemia (B- ALL) who are minimal residual disease positive at the end of consolidation therapy:” (2019-xxxx). DeSantes, site PI
NIH/NCI & Children’s Hospital of Philadelphia (U10 CA180886), “COG national clinical trials network group operations center” (2019-2025). DeSantes, site PI
Novartis & Children’s Hospital of Philadelphia (AALL0434), “Intensified methotrexate, nelarabine and augmented BFM therapy for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma” (2018-xxxx). DeSantes, site PI
St Baldrick’s Foundation & Children’s Hospital of Philadelphia (ALTE15N2), “LEAHRN (late effects after high-risk neuroblastoma) Study” (2018-xxxx). DeSantes, site PI
Children’s Oncology Group & Children’s Hospital of Philadelphia (APEC1621SC), “Pediatric MATCH (molecular analysis for therapy choice) screening” (2017-xxxx). DeSantes, site PI
Seagen, Inc. & Children’s Hospital of Philadelphia (AHOD1331), “A randomized phase III study of brentuximab vedotin (IND#117117) for newly diagnosed classical hodgkin lymphoma in children and adolescents” (2016-xxxx). DeSantes, site PI
Hoffmann-LaRoche, Inc. & Children’s Hospital of Philadelphia (ANHL1131), “Intergroup trial for children or adolescents with B-cell NHL or B-AL: evaluation of rituximab efficacy and safety in high risk patients” (2014-xxxx). DeSantes, site PI
Children’s Hospital of Philadelphia (AALL1131), “A phase III randomized trial for newly diagnosed high risk B-precursor acute lymphoblastic leukemia (ALL) testing clofarabine (IND #73789, NSC #606869) in the very high risk stratum” (2014-xxxx). DeSantes, site PI
Completed Support
NIH/NCI & Fred Hutchinson Cancer Center (UM1 CA154967), “3CI Study: Childhood cancer combination immunotherapy. Phase 1b and expansion study of Nivolumab combination immunotherapy in children, adolescent and young adult (CAYA) patients with relapsed/refractory hypermutant cancers” (2021-2022). DeSantes, site PI